The protective association between statins use and adverse outcomes among COVID-19 patients: a systematic review and meta-analysis
Preprint
Abstract
Introduction Statins may reduce a cytokine storm, which has been hypothesized as a possible mechanism of severe COVID-19 pneumonia. The aim of this study was to conduct a systematic review and meta-analysis to report on adverse outcomes among COVID-19 patients by statin usage. Methods Literatures were searched from January 2019 to December 2020 to identify studies that reported the association between statin usage and adverse outcomes, including mortality, ICU admissions, and mechanical ventilation. Studies were meta-analyzed for mortality by the subgroups of ICU status and statin usage before and after COVID-19 hospitalization. Studies reporting an odds ratio (OR) and hazard ratio (HR) were analyzed separately. Results Thirteen cohorts, reporting on 110,078 patients, were included in this meta-analysis. Individuals who used statins before their COVID-19 hospitalization showed a similar risk of mortality, compared to those who did not use statins (HR 0.80, 95% CI: 0.50, 1.28; OR 0.62, 95% CI: 0.38, 1.03). Patients who were administered statins after their COVID-19 diagnosis were at a lower risk of mortality (HR 0.53, 95% CI: 0.46, 0.61; OR 0.57, 95% CI: 0.43, 0.75). The use of statins did not reduce the mortality of COVID-19 patients admitted to the ICU (OR 0.65; 95% CI: 0.26, 1.64). Among non-ICU patients, statin users were at a lower risk of mortality relative to non-statin users (HR 0.53, 95% CI: 0.46, 0.62; OR 0.64, 95% CI: 0.46, 0.88). Conclusion Patients administered statins after COVID-19 diagnosis or non-ICU admitted patients were at lower risk of mortality relative to non-statin users.Keywords
All Related Versions
- Published version: PLOS ONE, 16 (6), e0253576.
This publication has 17 references indexed in Scilit:
- Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO studyDiabetes & Metabolism, 2021
- Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trialsAnnals of Palliative Medicine, 2020
- Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infectionDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19Cell Metabolism, 2020
- The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home ResidentsJournal of the American Medical Directors Association, 2020
- May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?Nutrition, Metabolism and Cardiovascular Diseases, 2020
- COVID-19 cytokine storm: the interplay between inflammation and coagulationThe Lancet Respiratory Medicine, 2020
- How robust are the results of one of the first positive trials exploring hydroxychloroquine for treatment of COVID-19?medRxiv, 2020
- Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 InfectionmBio, 2020
- The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activityVirology, 2013